Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug–drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine

Rivaroxaban (RIV; Xarelto; Janssen Pharmaceuticals, Beerse, Belgium) is one of the direct oral anticoagulants. The drug is a strong substrate of cytochrome P450 (CYP) enzymes and efflux transporters. This study aimed to develop a physiologically‐based pharmacokinetic (PBPK) model for RIV. It contain...

Descripción completa

Detalles Bibliográficos
Autores principales: Ngo, Lien Thi, Yang, Sung‐yoon, Shin, Sooyoung, Cao, Duc Tuan, Van Nguyen, Hung, Jung, Sangkeun, Lee, Jae‐Young, Lee, Jong‐Hwa, Yun, Hwi‐yeol, Chae, Jung‐woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662201/
https://www.ncbi.nlm.nih.gov/pubmed/36193622
http://dx.doi.org/10.1002/psp4.12844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662201/
https://www.ncbi.nlm.nih.gov/pubmed/36193622
http://dx.doi.org/10.1002/psp4.12844

Ejemplares similares